| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies (NCT05131022) | Nurix Therapeutics, Inc. | 2022-04-13 |
| Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) (NCT04745832) | MEI Pharma, Inc. | 2021-08-13 |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies (NCT04830137) | Nurix Therapeutics, Inc. | 2021-05-05 |
| Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies (NCT04767308) | Huazhong University of Science and Technology | 2021-03-01 |
| Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T (NCT04488354) | Calibr, a division of Scripps Research | 2021-01-21 |
| CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (NCT04450069) | Calibr, a division of Scripps Research | 2020-08-14 |
| Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma (NCT04431089) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2020-05-09 |
| Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels (NCT04537715) | Epizyme, Inc. | 2020-04-23 |
| ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) (NCT04049513) | Malaghan Institute of Medical Research | 2019-10-11 |
| Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) (NCT03768505) | MEI Pharma, Inc. | 2019-06-25 |
| REal World Data in LYmphoma and Survival in Adults (NCT03869619) | Hospices Civils de Lyon | 2018-11-14 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma (NCT03571828) | Amgen | 2018-10-29 |
| A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML (NCT03547115) | MEI Pharma, Inc. | 2018-05-31 |
| A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (NCT03460977) | Pfizer | 2018-04-17 |
| Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 (NCT03265158) | Royal Marsden NHS Foundation Trust | 2017-07-19 |
| A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma (NCT02914938) | MEI Pharma, Inc. | 2016-10-01 |
| A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study (NCT02875548) | Epizyme, Inc. | 2016-08-30 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (NCT02362035) | Acerta Pharma BV | 2015-02-20 |